Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 387

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 387
---
     4,200  
    $9.20  
    11/17/2034

    12/1/2023(1)
     745  
     2,236  
     551  
    11/30/2033
  
    James Bligh 
    11/18/2024(2)
     9,450  
     9,450  
    $9.20  
    11/17/2034

    11/18/2024(1)
     559  
     1,677  
     551  
    11/30/2033

    (1)
    The
    stock option vests as to 1/4 of the underlying shares on each of the first four anniversaries of the vesting commencement date
  
    (2)
    The stock options vests 50% of the grant date and 50% in three equal annual installments thereafter

2023
Stock Incentive Plan

On
September 20, 2023, MURF stockholders approved the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (the “2023 Plan”).
The 2023 Plan permits our board of directors or compensation committee to grant may grant or issue stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock units, other stock- or cash-based awards and dividend equivalents,
or any combination thereof, to officers, employees, directors or consultants of the Company.

Subject
to adjustment for stock splits or similar events, the 2023 Plan initially reserved 114,976 shares of Common Stock for issuance
pursuant to awards, plus an annual increase on the first day of each calendar year beginning in 2024 and ending in 2033 equal to the
lesser of (i) 5% of the shares of Common Stock outstanding on the last day of the immediately preceding calendar year and (ii) such
smaller number of shares of Common Stock as determined by our board of directors. The 2023 Plan was increased
by 36,914 shares of common stock effective January 1, 2024, and by 69,240 shares of common stock effective January 1,
2025. On February 6, 2025, the Company filed a registration statement on Form S-8 that increased the number of shares of Common
Stock available for issuance under the